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Abstract 
Rationale: Multiple myeloma (MM) is a multifocal malignancy of bone marrow plasma cells, characterized by 
vicious cycles of remission and relapse that eventually culminate in death. The disease remains mostly incurable 
largely due to the complex interactions between the bone microenvironment (BME) and MM cells (MMC). In 
the “vicious cycle” of bone disease, abnormal activation of osteoclasts (OCs) by MMC causes severe osteolysis, 
promotes immune evasion, and stimulates the growth of MMC. Disrupting these cancer-stroma interactions 
would enhance treatment response. 
Methods: To disrupt this cycle, we orthogonally targeted nanomicelles (NM) loaded with non-therapeutic 
doses of a photosensitizer, titanocene (TC), to VLA-4 (α4ß1, CD49d/CD29) expressing MMC (MM1.S) and 
αvß3 (CD51/CD61) expressing OC. Concurrently, a non-lethal dose of a radiopharmaceutical, 
18F-fluorodeoxyglucose ([18F]FDG) administered systemically interacted with TC (radionuclide stimulated 
therapy, RaST) to generate cytotoxic reactive oxygen species (ROS). The in vitro and in vivo effects of RaST were 
characterized in MM1.S cell line, as well as in xenograft and isograft MM animal models. 
Results: Our data revealed that RaST induced non-enzymatic hydroperoxidation of cellular lipids culminating 
in mitochondrial dysfunction, DNA fragmentation, and caspase-dependent apoptosis of MMC using VLA-4 avid 
TC-NMs. RaST upregulated the expression of BAX, Bcl-2, and p53, highlighting the induction of apoptosis via 
the BAK-independent pathway. The enhancement of multicopper oxidase enzyme F5 expression, which inhibits 
lipid hydroperoxidation and Fenton reaction, was not sufficient to overcome RaST-induced increase in the 
accumulation of irreversible function-perturbing α,ß-aldehydes that exerted significant and long-lasting damage 
to both DNA and proteins. In vivo, either VLA-4-TC-NM or αvß3-TC-NMs RaST induced a significant 
therapeutic effect on immunocompromised but not immunocompetent MM-bearing mouse models. Combined 
treatment with both VLA-4-TC-NM and αvß3-TC-NMs synergistically inhibited osteolysis, reduced tumor 
burden, and prevented rapid relapse in both in vivo models of MM. 
Conclusions: By targeting MM and bone cells simultaneously, combination RaST suppressed MM disease 
progression through a multi-prong action on the vicious cycle of bone cancer. Instead of using the standard 
multidrug approach, our work reveals a unique photophysical treatment paradigm that uses nontoxic doses of 
a single light-sensitive drug directed orthogonally to cancer and bone cells, followed by radionuclide-stimulated 
generation of ROS to inhibit tumor progression and minimize osteolysis in both immunocompetent murine and 
immunocompromised human MM models. 
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MM is neoplasia of plasma cells in the bone 
marrow and is the second most common 
hematological malignancy [1-7]. Clinically, the disease 
progresses from asymptomatic monoclonal 
gammopathy of undetermined significance (MGUS) 
and smoldering multiple myeloma (SMM) to an 
increase in the number of malignant plasma cells and 
the appearance of CRAB symptoms (hypercalcemia, 
renal failure, anemia, and bone lesions) [8-10]. At the 
pathogenetic level, several mutations can contribute 
to the clonal expansion of malignant plasma cells [7]. 
However, advanced MM and MGUS are often 
indistinguishable in the load and type of karyotypic 
and sequence abnormalities [11], suggesting a key role 
of MM cell-extrinsic factors in determining 
tumorigenic progression of bone lesions [12-15]. 
Indeed, several lines of evidence show that some 
pro-MM changes in BME accompany, or even 
precede, the appearance of bone lesions [16-19]. 
Bone marrow (BM), the primary anatomical site 
of hematopoiesis [1, 20-22], comprises diverse cell 
populations [23]. Particularly, hematopoietic cells 
localized in the BM interact extensively with the bone 
marrow stromal cells (BMSC) and cells that regulate 
bone morphology, including matrix-deposing 
osteocytes and osteoblasts of mesenchymal origin and 
bone-resorption osteoclasts (OCs) of myeloid lineage 
[24]. Together with the extracellular matrix proteins 
(ECM) [25-28], bone resident cells interact with MM 
cells to promote tumor growth, survival, immune 
suppression, and resistance to chemotherapy [17, 19, 
29-31]. These complex interactions result in osteolytic 
lesions, which occur in 90% of MM patients [32] with 
a high rate of skeletal-related events that affect 
morbidity, quality of life, and survival [33]. 
The extensive heterogeneity and high frequency 
of MM relapse require autologous stem cell 
transplantation for eligible patients and the 
administration of combination drugs that include 
immunomodulatory drugs (thalidomide, 
lenalidomide, pomalidomide), corticosteroids 
(dexamethasone), proteasome inhibitors (bortezomib, 
carfilzomib, ixazomib), deacetylase inhibitors 
(panobinostat), and monoclonal antibodies 
(Elotuzumab, Daratumumab) [34-42]. To prevent or 
minimize severe skeletal-related events, current 
therapies include inhibitors of bone resorption 
(zoledronic acid, pamidronates, denosumab) and 
radiation [32]. These interventions are used at 
sufficiently high doses to exert a therapeutic effect but 
also induce dose-limiting side effects. A strategy to 
overcome this challenge is to use sub-lethal doses of 
drugs and selectively enhance therapeutic effect in the 
target cells. 
MM and the BME provide a rich source of 
biomarkers for targeting diverse cells, including 
CD38, CS1, VLA-4, and αvß3 proteins. Previously, we 
demonstrated that VLA-4 integrin is upregulated on 
MM cells and MM protective lymphocytes and 
macrophages [43], thus constituting a useful 
therapeutic target. To minimize organ and systemic 
toxicity, we developed a new treatment paradigm 
called Cerenkov radiation-induced therapy where 
light-sensitive drugs (photosensitizers) can absorb 
Cerenkov radiation from radiopharmaceuticals [42, 
43] to generate cytotoxic ROS. We recently coined the 
term radionuclide stimulated therapy (RaST) to 
account for other potential contributing factors to the 
observed therapeutic effects other than Cerenkov 
radiation [44]. The ability of RaST to induce 
therapeutic effect only when the two components 
co-localize in the same or adjacent cells enables us to 
administer nontoxic amounts of both photosensitizers 
and radiopharmaceuticals to effect precision therapy. 
Using contact-facilitated drug delivery strategy [45, 
46], we recently demonstrated the high loading 
capacity and delivery of unmodified photosensitizers 
in NMs targeted to tumors [43]. Compared to large 
nanoparticles with limited diffusivity [47-49], the 
small size of the NMs (20 nm) facilitates the 
penetration and distribution in the highly 
vascularized and compartmentalized bone marrow 
where MM resides [50]. Despite the improvement in 
therapeutic response, the rate of MM relapse 
remained high, probably caused by either 
cell-intrinsic adaptations or protective interactions 
with the bone niche. Previous studies established that 
increased osteoclastogenesis and subsequent 
osteolytic activity are essential for MM survival [6, 
51]. OC differentiation and activity promote MM 
progression and relapse by stimulating proliferation 
and reactivation from dormancy of MMC [52]. The 
integrin αvß3, which is over-expressed on these cells 
but not in MM cells, plays a vital role in the osteolytic 
function of OCs [53, 54]. A unique benefit of RaST is 
that the photophysical ROS-generating mechanism is 
applicable in any targeted cell type, favoring the use 
of the same light-sensitive drug delivered 
orthogonally to targeted cells to achieve disparate 
multicellular therapy. 
In this study, we harnessed the orthogonal 
expression of VLA-4 on the cell surface of MM [55, 
56], and αvß3 on the plasma membrane of OCs [57, 
58], as well as the expression of GLUT1 (CD71) 
glucose transporter on both cell types [59-62] for a 
new intercellular RaST. Incorporation of the 
photosensitizer, TC, into NMs (20 nm) targeted to 
either αvß3 or VLA-4 allowed us to deliver TC 
selectively to OC and MM cells, respectively. Using 





[18F]FDG to initiate ROS generation, we elucidated the 
mechanism of RaST-induced cell death (Figure 1). Our 
results point to a paradigm where the direct depletion 
of pro-tumorigenic cells in the BME combines with a 
multidimensional cell death mechanism to achieve a 
sustainable therapeutic effect in a disease that 
currently remains incurable. By using the same drug 
to treat both cell types, we mitigated the cumulative 
toxic effects of multidrug therapy on healthy tissue. A 
requirement for treating MM patients with relapsed 
disease is to add at least a drug from a non-refractory 
group. With many pharmacologic drugs unable to 
meet this threshold, multicellular RaST is a potential 
standalone therapy or a component of multidrug 
therapy of MM and other bone lesions. 
Methods 
Cell lines and reagents 
MM1.S human MM [63] and 5TGM1 murine MM 
[64] cell lines, either naïve or carrying Click Beetle Red 
(CBR) luciferase and Green Fluorescent Protein (GFP) 
reporters (MM1.S/CBR/GFP and 5TGM/CBR/GFP, 
respectively), as well as MM1.S/CBR/GFP resistant 
to RaST and MM1.S/CBR/GFP without CD49d, were 
generously provided by Dr. DiPersio (Washington 
University School of Medicine, WUSM, St. Louis). 
Cells were routinely cultured in complete medium 
(CM) consisting of Iscove’s Modified Dulbecco’s 
Media (Thermo Fisher Scientific, Waltham, MA) 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS, ThermoFisher Scientific, Waltham, MA) 
and 50 µg/mL Gentamycin (Thermo Fisher Scientific, 
Waltham, MA). The cells were routinely washed in 
phosphate-buffered saline (PBS, Thermo Fisher 
Scientific, Waltham, MA), pH 7.4. VLA-4 and αvß3 
targeted NM were loaded with TC 
(Bis(cyclopentadienyl)titanium(IV) dichloride, 
Sigma-Aldrich, St. Louis, MO) [43, 46]. Protein content 
was routinely measured with PierceTM bicinchoninic 
acid (BCA) assay (Thermo Fisher Scientific Waltham, 
MA). 
Synthesis of VLA4-PEG2000-PE 
A VLA-4 antagonist based on the highly 
selective LLP2A [65] peptidomimetic, which binds 
selectively to activated α4ß1 heterodimers [65] was 
synthesized and coupled to polyethylene glycol–
phosphatidyethanolamine anchor. Briefly, rink amide 
4-methylbenzhydrylamine resin (MBHA) resin was 
fluorenylmethyloxycarbonyl chloride (Fmoc) 
deprotected with 20% piperidine in dimethyl-
formamide (DMF). Fmoc-Ach-OH dissolved in 
hydroxy-benzotriazole (HOBt) and 1,3-diisopropyl-
carbodiimide (DIC) in DMF was coupled at RT for 2 h. 
The Fmoc deprotection with 20% piperidine, and 
serial coupling and deprotection cycles with 
Fmoc-Aad(tBu) and Fmoc- Lys(Dde) were performed. 
After removal of Fmoc, a solution of 2-(4-(3-o- 
tolylureido)phenyl)acetic acid, HOBt and DIC in DMF 
 
 
Figure 1. Schematic illustration of orthogonal RaST. NMs are loaded with a light-sensitive drug, TC, but directed to different cells that express VLA-4 (MM) and αvß3 
(OCs) in the BM. The expression of GLUT1 on both MM and OCs provides additional selectivity for eradicating only cells that express GLUT1 and either VLA-4 or αvß3. 





was added overnight, washed, and the Dde protecting 
group removed with 2% hydrazine in DMF. A 
solution of trans-3-(3-pyridyl) acrylic acid, HOBt and 
DIC in DMF was added and coupling was ensured via 
a negative Kaiser test. The crude product was cleaved 
with 95% trifluoroacetate (TFA): 2.5% water: 2.5% 
triisopropylsilane, precipitated with diethyl ether and 
purified using RP-HPLC. VLA-4 ligand dissolved in 
ethanol was mixed with 2-iminothiolane in methanol 
and allowed to react for 2 h @ 25 ºC. N-(4-(P- 
maleimidophenyl) butyrl)-phosphatidylethanolamine 
(MPB-PEG2000-DSPE) was added and incubated for 2 
h. The purified lyophilized sample was a white solid 
(VLA-4-PEG-PE, Calculated, 3781; Observed, m/z. 
3780). 
Synthesis of αvß3-integrin antagonist 
The αvß3-integrin antagonist was a quinalone 
nonpeptide developed by Bristol-Myers Squibb 
Medical Imaging (US patent 6,511,648 and related 
patents), which was initially reported and 
characterized as the 111In-DOTA conjugate RP478 and 
cyan 5.5 homologue TA145 [66]. The specificity of the 
αvß3 ligand mirrors that of LM609 and has a 15-fold 
preference for the Mn2+ activated receptor (21 nM) 
[67]. The IC50 estimates for αvß5, α5ß1 and GP IIbIIIa 
were > 10 µM (BMSMI, Billerica, MA, USA, US patent 
6,511,648 and related patents). The antagonist amide 
coupled to PEG2000-phosphatidylethanolamine (αvß3- 
PEG-PE) was a gift from Kereos, Inc., St. Louis, MO. 
(Calculated: 4021, Observed: m/z 4020). 
Synthesis of VLA-4-TC-NM and αvß3-TC-NM 
Targeted titanocene nanomicelles were prepared 
as previously described [43]. Briefly, phospholipid/ 
polysorbate 80 micelles were prepared as a 
microfluidized suspension comprised of 20% 
polysorbate tween 80 (v/v) (NOF America, White 
Plains, NY), a 2.0% (w/v) surfactant commixture, and 
1.7% (w/v) glycerin in filtered MilliQ Nanopure 
water. The surfactant commixture included 0 or 2 
mole% titanocene dichloride (TiCl2, Sigma-Aldrich, 
St. Louis, MO) and 0 or 0.15 mole% of a 
VLA4-PEG-PE or αvβ3-PEG-PE with the remainder 
phosphatidylcholine (>98% purity, NOF America, 
White Plains, NY). The surfactant components were 
dried from organic solvent into a film, resuspended in 
nanopure water, and combined with polysorbate 80, 
buffer, Nanopure water, and glycerin. The mixture 
was sonicated at 4 °C for 3 min, then microfluidized 
(LV1, Microfluidics, Westwood, MA) at 20,000 psi for 
5 passes. Dynamic light scattering (DLS) 
physicochemical characteristics (nominal of 10 
estimates) of the αvß3-NM were: particle size: 18 ± 2 
nm, polydispersity: 0.2 ± 0.02, zeta potential 1.4 ± 0.6 
mV and for the VLA-4-NM were: particle size: 20 ± 1.4 
nm, polydispersity: 0.3 ± 0.01, zeta potential: -0.3± 0.2 
mV. The NM were filtered with 0.2 µm filter into 
sterile serum vials, preserved under inert gas, capped 
and crimp-sealed, then stored at 4 °C until use. 
Further data schematically illustrating the NM and 
TEM, as well as the titanocene NM pharmacokinetic 
and biodistribution were previously described [43]. 
[18F]FDG production 
[18F]FDG was produced with an average specific 
activity 70-299 mCi/mL by the Mallinckrodt Institute 
of Radiology’s Cyclotron Facility and Nuclear 
Pharmacy at Washington University School of 
Medicine in compliance with current good 
manufacturing practices. 
Murine osteoclast differentiation 
Bone marrow macrophages (BMM) were 
isolated and induced to differentiate into OCs 
according to previously methodology [68], with 
modifications. Fox Chase SCID beige or 
C57BL/6-KaLwRij male mice (5-7 weeks old) were 
euthanized, and femurs and tibiae were aseptically 
dissected. Both ends of bones were removed, and 
bone marrow was extracted using centrifugation at 
10,000 × g for 10 s. The pellet was suspended in 
Roswell Park Memorial Institute 1640 medium 
(RPMI-1640) supplemented with 10% heat-inactivated 
HyClone defined Fetal Bovine Serum (Thermo Fisher 
Scientific, Waltham, MA) and 50 µg/mL Gentamicin 
(RPMI-10G) containing 5 × 10-6 mg/mL recombinant 
mouse M-CSF (R&D Systems, Minneapolis, MN) and 
plated on 10 cm Petri dishes (Valmark, Thomas 
Scientific, Swedesboro, NJ). The plating density of 
BMM from 2 mice for each plate was routinely 
maintained. The plates were incubated overnight at 37 
°C and humidified 5% CO2 atmosphere. The 
non-adherent cells were harvested, washed once with 
RPMI-10G, and plated on 24-well tissue culture plates 
(TPP, Midwest Scientific, Valley Park, MO) at 4 × 105 
cells per well in RPMI-10G supplemented with 100 
ng/mL RANKL (R&D Systems, Minneapolis, MN). 
The medium was renewed every 72 h for a minimum 




assay, a colorimetric assay for assessing cell viability, 
was performed using CellTiter 96® Aqueous One 
Solution Cell Proliferation Reagent (Promega, 
Madison, MI). After treatment, the CM was carefully 
removed from each well and replaced with 0.5 mL of 
PBS containing 50 µL tetrazolium compound 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carbooxymethoxyp





henyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; 
MTS) and phenazine ethosulfate (PES, electron 
coupling reagent) (CellTiter 96® Aqueous One 
Solution Cell Proliferation Reagent, Promega, 
Madison, WI) to determine the percentage of live 
cells. The plates were incubated at 37 °C for 1-4 h to 
allow the tetrazolium compound to develop. The 
resulting absorbance was detected at 490 nm with a 
Synergy/NEO2 multi-mode reader (BioTek, 
Winooski, VT). 
In vitro RaST 
In vitro RaST experiments were performed in 24 
well plates containing 4 x 105 cells per well in 1 mL of 
CM. The treatment was initiated by the addition of 
either VLA-4-TC-NM (5 µL per well, 0.5 µg TC) or 
αvß3-TC-NM (5 µL per well, 0.5 µg TC), or their 
combination. The NM were allowed to bind to target 
receptors at 4 °C for 1 h. The medium with unbound 
NM was carefully removed and replaced with 1 mL 
fresh medium. At this time, 3.7 MBq/mL (0.1 mCi) 
[18F]FDG in saline was added to the appropriate wells, 
and the plates were placed in the 37 °C/5% CO2 
humidified atmosphere for the indicated amounts of 
time. After the completion of treatment, the medium 
was carefully removed and 0.5 mL of PBS containing 
50 µL MTS reagent (CellTiter 96® Aqueous One 
Solution Cell Proliferation Reagent, Promega, 
Madison, WI) was added to each well to determine 
the percentage of live cells. The plates were incubated 
at 37 °C for 1-4 h to allow the tetrazolium compound 
to be reduced to form formazan dye. The resulting 
absorbance was detected at 490 nm with a 
Synergy/NEO2 multi-mode reader (BioTek, 
Winooski, VT). The data were reported as a percent of 
live cells compared to the untreated cells (100%). 
Reactive oxygen species assay 
TC is a photosensitizer and is known to generate 
ROS upon irradiation by UV light or Cerenkov 
radiation [69, 70]. ROS measurements were carried 
out at RT using 2’,7’-dichlorodihydrofluorescein 
diacetate (H2DCFDA, Thermo Fisher Scientific, 
Waltham, MA) as ROS indicator. RaST treatments 
were performed as described in the in vitro RaST 
section. After the VLA-4-TC-NM RaST and the 
controls were added to the appropriate wells, 
H2DCFDA was added to each well as follows. 
H2DCFDA was reconstituted in DMSO immediately 
prior to being added to each well at 5 µM final 
concentration and the plates were incubated in 
humidified atmosphere at 37 °C/5% CO2 for 72 h. At 
the end of the incubation period, the dye was excited 
at 495 nm and the emitted fluorescence was detected 
at 520 nm with a Synergy/NEO2 multi-mode reader 
(BioTek, Winooski, VT). The cells were mechanically 
harvested with a rubber-tipped cell scraper (Sarstedt, 
Newton, NC), washed twice with PBS, lysed with 200 
µL RIPA buffer at 4 °C for 30 min and the total protein 
content was determined with the BCA assay. The data 
were reported as fluorescence intensity per µg of 
protein. 
Oxidative stress markers profile 
Three oxidative stress markers were included in 
the matabolomic analysis of MM1.S cells: 3β,5α,6β- 
trihydroxycholestane (triol, CAS 1253-84-5), 
7-ketocholesterol (CAS 566-28-9), and 
malondialdehyde (MDA, CAS 542-78-9). To 
investigate the oxidative stress markers resulting from 
RaST, the cells were treated with VLA-4-TC-NM RaST 
or left untreated as in the in vitro RaST section. At the 
end of treatment, the cells were mechanically 
harvested with a rubber-tipped cell scraper (Sarstedt, 
Newton, NC) and washed twice with PBS. The 
cultured cell samples were lysed with 200 μL of 4:1 
MeOH/Water, containing 10 ng each of deuterated 
triol-d7, deuterated 7-ketocholesterol-d7, deuterated 
4-hydroxy nonenal-d3 (4-HNE-d3), and deuterated 
4-hydroxy hexenal-d3 (4-HHE-d3) as internal 
standards. An aliquot (50 μL) of the cell lysate was 
dried under a stream of nitrogen. The sterol markers 
were derivatized with dimethylglycine (DMG), while 
the aldehyde markers in the second aliquot (50 μL) 
were derivatized with O-benzylhydroxylamine to 
improve MS sensitivity as well as chromatographic 
properties. The analysis was performed using a 
Shimadzu 20AD HPLC system coupled to a tandem 
mass spectrometer (API-6500+Qtrap: Applied 
Biosystems, Waltham, MS) operated in multiple 
reaction monitoring mode (MRMM). The positive ion 
spray ionization mode (ESIM) was used for detection 
of analytes and the internal standards. The samples 
were injected in triplicate for data averaging. Data 
processing was conducted with Analyst 1.6.3 software 
(Applied Biosystems, Waltham, MS). For each 
analyte, the peak area was calculated and compared 
to the peak area of the corresponding internal 
standard. The resulting ratios for each analyte were 
reported as relative abundance. 
Lipid hydroperoxide assay 
Lipid hydroperoxide measurements were 
performed using the lipid hydroperoxide test 
(Northwest Life Sciences Specialties, LLC, Vancouver, 
WA). Intracellular lipid peroxides oxidize ferrous iron 
(Fe2+) to form ferric iron (Fe3+). The amount of Fe3+ 
reflects the lipid peroxide content and is detected by 
its reaction with 3,3’-Bis[N,N-bis(carboxymethyl)-
aminomethyl]-o-cresolsulonephtalein (Xylenol 





Orange). MM1.S cells were either treated with 
VLA-4-TC-NM RaST, VLA-4-TC-NM alone, [18F]FDG 
alone or left untreated for 72 h. The cells were then 
mechanically harvested, lysed, 10 µL lysate aliquots 
from each well were reserved for the protein content 
measurement, and treated with catalase to inactivate 
endogenous H2O2. The lysates were reacted with the 
ferrous iron reagent. The resulting Fe3+ was detected 
with Xylenol Orange as a chromogen at 560 nm using 
Synergy/NEO2 multi-mode reader (BioTek, 
Winooski, VT). The data was normalized to protein 
content of each sample measured with PierceTM BCA 
protein assay kit (Thermo Fisher Scientific, Waltham, 
MA) and reported as OD per µg of protein. 
Caspase-3 assay 
Caspase 3 levels were determined with 
Apo-ONE® Homogeneous Caspase-3/7 Assay kit 
(Promega, Madison, WI). MM1.S cells were plated in 
24 well plates at 4 × 105 per well in CM and either left 
untreated or treated with VLA-4-TC-NM RaST, 
VLA-4-TC-NM alone, and [18F]FDG alone for 72 h as 
described in the in vitro RaST section. Each condition 
was tested in triplicate. At the end of treatment, the 
CM was replaced with 250 µL PBS and 250 µL Apo- 
ONE® Homogeneous Caspase-3/7 reagent rhodamine 
110, (bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L- 
aspartic acid amide; Z-DEVD-R110) was added to the 
wells. The intracellular active Caspase 3/7 removed 
the DEVD peptides and released the strongly 
fluorescent R110, which was then excited at 499 nm, 
and the resulting fluorescence was detected at 521 nm 
with a Synergy/NEO2 multi-mode reader (BioTek, 
Winooski, VT). Fluorescence intensities from 
VLA-4-TC-NM RaST, VLA-4-TC-NM alone, and 
[18F]FDG alone were compared to the fluorescence 
intensity obtained from the untreated cells and 
expressed as a ratio over the untreated cells. 
Flow cytometry 
DNA fragmentation, such as double-strand 
breaks, and the associated upregulation of the DNA 
repair mechanisms is one of the downstream effects of 
intracellular oxidative stress damage. The degree of 
DNA repair process was assessed by measuring the 
level of γH2AX, a phosphorylated histone variant 
[71]. MM1.S cells were treated with VLA-4-TC-NM 
RaST, VLA-4-TC-NM, [18F]FDG or left untreated for 
72 h as described in the in vitro RaST section. At the 
end of the incubation period, the cells were 
mechanically harvested, and washed three times with 
FACS buffer (PBS supplemented with 0.1% FBS). 
After the cells were permeabilized with BD 
Phosflow™ Perm III buffer (BD Biosciences, San Jose, 
CA), the staining was performed with mouse 
anti-human γH2AX PE-pS139, clone N1-431 (BD 
Biosciences, San Jose, CA), 0.5 µg/106 cells for 60 min 
at 4 °C. Concurrently, the cell cycle phases of cells that 
have undergone treatment and the controls were 
determined with the 4′,6-diamidino-2-phenylindole 
stain (DAPI, BD Biosciences, San Jose, CA) at 8 µg/106 
cells. The dead cells were identified and quantified 
using the membrane-impermeable dye Propidium 
iodide staining solution (PI, BD Biosciences, San Jose, 
CA). The expression levels of CD49d, CD61, CD71, 
and GLUT1 were determined using the following 
antibodies: PE mouse anti-human CD49d clone 9F10, 
FITC mouse anti-human CD51/CD61 clone 23C6, PE 
mouse anti-human CD71 clone M-A712, Alexa Fluor 
647 mouse anti-human GLUT1 (all from BD 
Biosciences, San Jose, CA). The stained cells were 
analyzed with the Gallios flow cytometer (Beckman 
Coulter Life Sciences, Brea, CA) and the resulting data 
were quantified with FlowJo software (Ashland, OR). 
Ferroptosis inhibition with Ferrostatin-1 
Ferroptosis inhibitor 3-amino-4-(cyclohexyl-
amino)-benzoic acid, ethyl ester (FST-1, Cayman 
Chemical, Ann Arbor, MI) was used to investigate the 
involvement of Ferroptosis in RaST-mediated cell 
death. MM1.S were plated and either left untreated or 
treated with VLA-4-TC-NM RaST, as well as VLA-4 
and FDG controls, as described in the in vitro RaST 
section. FST-1 (10 µM) was added concomitantly with 
the VLA-4-TC-NM RaST treatment. After 72 h 
incubation at 37 °C/5% CO2 humidified atmosphere, 
the CM was carefully removed from each well and 
replaced with 0.5 mL of PBS containing 50 µL 
tetrazolium compound (CellTiter 96® Aqueous One 
Solution Cell Proliferation Reagent, Promega, 
Madison, WI) to determine the percentage of live 
cells. The plates were incubated at 37 °C for 1-4 h to 
allow the tetrazolium compound to develop. The 
resulting absorbance was detected at 490 nm with a 
Synergy/NEO2 multi-mode reader (BioTek, 
Winooski, VT). 
Western immunoblot assay 
MM1.S cells were treated with VLA-4-TC-NM 
RaST, VLA-4-TC-NM, [18F]FDG or left untreated for 
72 h as described in the in vitro RaST section. 
Following treatment, the cells were mechanically 
dissociated from 24-well plates using rubber-tipped 
cell scrapers (Sarstedt, Newton, NC) and washed 3 
times with PBS. Cells were then incubated with 25 
mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS buffer (RIPA lysis 
buffer, Abcam, Cambridge, MA) supplemented with 
EDTA-free protease inhibitor cocktail (Pierce, 
ThermoFisher, Waltham, MA) for 60 min at 4 °C 





followed by centrifugation at 12,000 x g for 10 min. 
Protein content was quantified using the BCA protein 
assay (Pierce, ThermoFisher Scientific, Waltham, 
MA). Lysates (50 µg total protein) were denatured for 
5 min at 100 °C and proteins were separated by 
sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) at 100 V for 1.5 h using 
Mini-PROTEAN TG precast gels with 
Tris/Glycine/SDS buffer system (BioRad, Hercules, 
CA). The proteins were transferred to a 
polyvinylidene fluoride membrane at 50 V for 2 h 
(PVDF, Millipore, Burlington, MA). After blocking for 
1 h in TBST blocking buffer (10 mM Tris-HCl, 150 mM 
NaCl, and 0.05% [v/v] Tween-20, pH 7.5, 5% (w/v) 
non-fat milk), the PVDF membrane was rinsed once 
with TBST and incubated overnight at 4 °C with 1° 
antibody diluted in TBST blocking buffer. After two 
washes, 5 min each, the membrane was incubated 
with 2° antibodies conjugated with horseradish 
peroxidase (HRP) for 1 h at room temperature. The 
unbound secondary antibody was removed with 3 
washes in TBST, 10 min each. Bound 2° antibodies 
were detected using SuperSignalTM West Pico Plus 
Detection Substrate (Thermo Fischer Scientific, 
Waltham, MA) and ChemiDocTM Imager (BioRad, 
Hercules, CA). The following 1° antibodies were used 
for immunoblotting: CD61 (1:1000, unconjugated, 
clone SJ19-09, Novus Biologicals, Centennial, CO); 
GLUT1 (1:1000, unconjugated, clone D3J3A, Cell 
Signaling Technology, Danvers, MA); Bak (1:1000, 
unconjugated, #3814, Cell Signaling Technology, 
Danvers, MA); Bax (1:1000, unconjugated, #2772, Cell 
Signaling Technology, Danvers, MA); p53 (1: 1000, 
unconjugated, clone 1C12, Cell Signaling Technology, 
Danvers, MA); Bcl-2 (1:1000, unconjugated, clone 
D17C4, Cell Signaling Technology, Danvers, MA); 
α-actin (1:1000, unconjugated, #4967, Cell Signaling 
Technology, Danvers, MA). The following 2° 
antibodies were used for immunoblotting: anti-rabbit 
IgG-HRP (1:10000, conjugated to HRP, sc-2357, Santa 
Cruz Biotechnology, Dallas, TX). 
Mass Spectrometry-based Label-free Protein 
Quantification 
The MM1.S cells were treated with 
VLA-4-TC-NM RaST or left untreated as stated in the 
in vitro RaST section. Each condition was performed 
in triplicate. At the end of treatment, the cells were 
mechanically harvested with a rubber-tipped cell 
scraper (Sarstedt, Newton, NC) and washed twice 
with PBS. Samples were subjected to reduction for 10 
min (10 mM TCEP/50 mM ammonium bicarbonate 
pH 8/100 µL) and alkylation for 30 min (25 mM 
Iodoacetamide), both at room temperature, followed 
by digestion with 0.5 µg trypsin (SOLu-Trypsin 
Dimethylated, Sigma) at 37 °C overnight. The digest 
was acidified to the final 1% TFA before cleaning up 
with Pierce C18 tip (Thermo Fisher Scientific, San 
Jose, CA) following the vendor’s instruction. The 
extracted peptides were dried and resuspended prior 
to LC-MS/MS analysis. 
LC-MS/MS analysis was carried out on an 
Orbitrap Fusion Lumos (Thermo Fisher Scientific, San 
Jose, CA) mass spectrometer coupled with a U3000 
RSLCnano HPLC (Thermo Fisher Scientific, San Jose, 
CA). The peptide separation was carried out on a 75 
µm × 50 cm PepMap C18 column (Thermo Fisher 
Scientific, San Jose, CA) at a flow rate of 0.3 μL/min 
and the following gradient: time = 0-4 min, 2% B 
isocratic; 4-8 min, 2-10% B; 8-83 min, 10-25% B; 83-97 
min, 25-50% B; 97-105 min, 50-98% B. Mobile phase 
consisted of A: 0.1% formic acid; mobile phase B: 0.1% 
formic acid in acetonitrile. The instrument was 
operated in the data-dependent acquisition mode in 
which each MS1 scan was followed by higher-energy 
collisional dissociation (HCD) of as many precursor 
ions in 2-second cycle (Top Speed method). The mass 
range for the MS1 was done using the FTMS was 365 
to 1800 m/z with resolving power set to 60,000 at 400 
m/z and the automatic gain control (AGC) target set 
to 1,000,000 ions with a maximum fill time of 100 ms. 
The selected precursors were fragmented in the ion 
trap using an isolation window of 1.5 m/z, an AGC 
target value of 10,000 ions, a maximum fill time of 100 
ms, a normalized collision energy of 35 ms, and an 
activation time of 30 ms. Dynamic exclusion was 
performed with a repeat count of 1, exclusion 
duration of 30 s, and a minimum MS ion count for 
triggering MS/MS set to 5000 counts. 
Sequence mapping and label-free quantification 
were done using Proteome Discoverer (version PD 
2.3). Database searches were established against the 
Human reference proteome (Uniprot.org) with the 
Byonic search engine launched by PD. The digestion 
enzyme was trypsin. Oxidation of methionine and 
acetylation of N-terminal of protein were specified as 
variable modifications. Protein quantification was 
achieved by using total intensities of all precursors. 
Pathways discoveries were performed using the 
Kyoto Encyclopedia of Genes and Genomes (KEGG), 
the WiKiPathways database, and the REACTOME 
Pathway database. 
Histology 
Femurs from treated and control animals were 
excised at predetermined time points and 
immediately placed in 10% neutral buffered formalin 
solution (VWR, West Chester, PA), where they 
remained for 48 h. The femurs were rinsed six times 
with PBS for 15 min each and decalcified with 14% 





EDTA for two weeks. After decalcification, the femurs 
were rinsed six times with PBS for 15 min each. The 
femurs were hydrated consecutively with 30%, 50%, 
and 70% alcohol for 15 min each. The femurs were 
embedded in paraffin, and 5 µm sections were 
obtained. The sections were stained with 
Hematoxylin/Eosin (H&E) and the Tartrate Resistant 
Acid Phosphatase (TRAP) stains by the Washington 
University Musculoskeletal Research Core. The 
stained sections were imaged with the Zeiss Axio 
Scan.Z1 (Zeiss-USA, San Diego, CA), and the images 
were analyzed with the ZEN 2.3 software (Zeiss-USA, 
San Diego, CA). Positive TRAP stain cells from the 
entire section were counted and presented as OC per 
section. 
Animal models 
All animal experiments were conducted in 
compliance with Washington University School of 
Medicine (WUSM) Institutional Animal Care and Use 
Committee (IACUC) guidelines and the Guide for the 
Care and Use of Laboratory Animals. Female Fox 
Chase SCID beige mice (5-6 weeks old) were obtained 
from Charles River Laboratory (Wilmington, MA). 
C57BL/6-KaLwRij mice predisposed to MM [72, 73] 
were obtained from Dr. Greg Mundy (OsteoScreen, 
Inc., San Antonio, TX) and maintained at WUSM 
animal facility. Animals purchased from vendors 
were allowed to acclimate for 1 week prior to studies 
and all animals were provided with food and water ad 
libitum. When needed, euthanasia was performed by 
cervical dislocation after anesthesia with 5% 
isoflurane (Pivetal®, DCM, WUSM). Prior to cell 
implantation, each cell line was tested for the reporter 
expression by performing in vitro BLI with 1 x 105 cells 
plated in a black 96-well plate. MM1.S cells (1 x 106 
per mouse in 100 µL saline) were injected 
intravenously (tail vein) in Fox Chase SCID beige 
mice for the xenograft MM model. 5TGM cells (1 x 106 
per mouse in 100 µL saline) were injected 
intravenously (tail vein) in C57BL/6-KaLwRij mice 
for the isograft MM model. Tumor progression was 
monitored by detection of live cells with BLI. 
Bioluminescent imaging (BLI) 
In vivo bioluminescence imaging of animals 
bearing MM1.S/CBR/GFP and 5TGM/CBR/GFP 
cells was performed on the days indicated with an 
IVIS Lumina (PerkinElmer, Waltham, MA; Living 
Image 3.2, 1-300 sec exposures, binning 2-8, FOV 
12.5cm, f/stop 1, and open filter). Mice were injected 
intraperitoneally with 150 mg/kg D-luciferin in PBS 
(Gold Biotechnology, St. Louis, MO) and imaged 10 
min later under isoflurane anesthesia (2%, vaporized 
in O2). Total photon flux (radiance, 
photons/sec/cm2/steradian) was measured from 
fixed region of interest (ROI) over the entire ventral 
side of the mice using Living Image 2.6. A precipitous 
drop in photon flux was considered to be an 
indication of defective circulation and the affected 
animal was removed from the observation group. 
In vivo RaST 
In vivo RaST was performed in disseminated 
xenograft and isograft models. Animals (n = 5 per 
group) were systemically implanted with 1 × 106 of 
either MM1.S/CBR/GFP (5-6 weeks old male Fox 
Chase SCID beige mice) or 5TGM/CBR/GFP (5-6 
weeks old male C57BL/6-KaLwRij mice) cells 
through the tail vein. Six days after implantation, 
tumor progression was determined using BLI 
(baseline). Animals with a whole-body flux of about 1 
x 106 were fasted for 16 h and treated with 
αvß3-TC-NM + VLA-4-TC-NM RaST, αvß3-TC-NM 
RaST, VLA-4-TC-NM RaST, or left untreated. Each 
αvß3-TC-NM RaST and VLA-4-TC-NM RaST 
treatment consisted of 50 µL NM (5 µg TC) mixed 1:1 
with saline to minimize viscosity. The αvß3-TC-NM + 
VLA-4-TC-NM RaST treatment consisted of 50 µL (5 
µg TC) of each NM type mixed with 50 µL saline. 
[18F]FDG (29.6 MBq/animal) was administered 
intraperitoneally 60-90 min later. The therapy was 
repeated once weekly for 5 weeks and monitored with 
weekly BLI. 
Data analysis and statistics 
In vitro RaST experiments were repeated three 
times with each condition performed in triplicate to 
control for the intra-experimental variability. The 
experiments were not randomized and the analysis 
was not blind. Metabolomics and proteomics studies 
were conducted using triplicate samples for each 
condition. In vivo RaST sample sizes were determined 
using previous experience [74]. Specifically, the 
sample size would depend on the effect size as 
defined by the mean difference between untreated 
and treated groups. For example, two-sided t-test 
would predict a sample size of n = 5 with 80% power 
to detect an effect size of 2.1 with a type I error rate of 
0.05. Quantification of OC in bone sections was 
performed using both femurs from n = 5 animals per 
condition. Data and statistical analyses were 
performed using GraphPad Prism 9.0.1 (151) 
(GraphPad Software, Inc., La Jolla, CA) and Microsoft 
Excel. For data with two groups and one variable, a 
two-tailed unpaired t-test was used. Data with one 
variable and multiple groups were analyzed with a 
one-way ANOVA and Tukey’s or Dunnett’s multiple 
comparisons test to determine the adjusted P-value. 
Data with two variables and multiple groups were 





analyzed with a two-way ANOVA and Tukey's 
multiple comparisons test to determine the adjusted 
P-value. 
The data were expressed as mean ± SD, unless 
indicated otherwise. Differences at the 95% 
confidence level (P < 0.05) were considered to be 
statistically significant. 
Results 
Convergence of nontoxic doses of TC and 
[18F]FDG in VLA-4 (MM) expressing cells 
selectively inhibits tumor proliferation 
Conjugation of drugs to biological carriers for 
delivery to different cell types presents several 
challenges, including modifying the drug’s intrinsic 
properties, pharmacokinetics, and intracellular 
distribution that could disrupt drug action. To 
circumvent these hurdles, we loaded the same 
amount of non-modified TC inside unilamellar 
phospholipid NMs using the method we reported 
previously [75]. A small-molecule peptidomimetic 
(LLP2A) that targets activated VLA-4 [43] or a 
quinolone molecule that has a high affinity for 
activated αvß3 [49] were inserted onto the surface of 
the NMs to obtain VLA-4-TC-NMs and αvß3-TC- 
NMs, respectively. Using the VLA-4-expressing 
human myeloma cell line, MM1.S [65], we determined 
the optimal non-therapeutic doses for both TC and 
[18F]FDG to prevent intrinsic toxicity by the RaST 
component at high doses. Treatment of MM1.S cells 
with increasing amounts of VLA-4-TC-NMs resulted 
in dose-dependent cell death after incubating for 24 h. 
While 0.5 µg, 2.5 µg, and 5 µg TC killed about 25%, 
25%, and 75% of the MM cells, respectively, treatment 
with 0.1 µg TC produced no appreciable cell death 
(Figure 2A). Similarly, [18F]FDG killed less than 20% 
of the cells at <1 mCi after 24 h (Figure 2B). Based on 
these results, we chose the lowest amount of TC (0.1 
µg) and [18F]FDG (0.1 mCi) for subsequent in vitro 
RaST studies. 
A delayed cytotoxic effect of RaST was observed 
at 72 h after treating MM1.S cells with the nontoxic 
amounts of VLA-4-TC-NM and [18F]FDG (Figure 2C). 
Using the 72 h time point, we demonstrated that the 
response of MM1.S cells to VLA-4-TC-NM RaST 
required the co-localization of both TC and [18F]FDG 
to exert a sustainable cell-killing effect (Figure 2D). By 
contrast, RaST was ineffective in killing 
RaST-resistant MM1.S cells which have low VLA-4 
expression [43] or genetically modified VLA-4 
knockout MM1.S cells [43] (Figure 2D). Taken 
 
 
Figure 2. Non-lethal amounts of TC and [18F]FDG converge in target cells to induce cell death. (A) VLA-4 targeted NM loaded with 0.1 µg TC did not lead to cell 
death; Quantitative data are shown as percent of live cells compared to the untreated cells. (B) [18F]FDG administered at 3.7 MBq-27.75 MBq (0.1 mCi-0.75 mCi) induce 
moderate degree of cell death; (C) VLA-4-TC-NM RaST induced about 40% MM1.S cell death 72 h after treatment; statistical significance was determined using unpaired 
two-tailed t-test and a 95% confidence level. The difference between 48 h and 72 h VLA-4-TC-NM RaST was significant (P = 0.0228). (D) VLA-4-TC-NM RaST-induced cell death 
requires the expression of VLA-4 by MM1.S cells; MM1.S cells expressing VLA-4 (WT) were compared to VLA-4-TC-NM RaST-resistant MM1.S cells (NR) expressing low levels 
of VLA-4 and VLA-4 knockout cells (CD49dKO). The data were analyzed with one-way ANOVA and Dunnett's multiple comparisons tests. Untreated versus RaST + WT: P < 
0.0001; untreated versus VLA-4-TC-NM RaST + RaST-resistant (RaSTNR) cells: P = 0.0473. 





together, these data demonstrate a synergistic 
interaction between nontoxic doses of a 
photosensitizer and a radionuclide capable of 
emitting Cerenkov radiation to exert specific and 
durable therapeutic effects on cancer cells. 
VLA-4-TC-NM RaST increases ROS and 
non-enzymatic lipid hydroperoxidation in 
MM1.S cells 
Overproduction of ROS leads to non-enzymatic 
peroxidation of lipids in plasma and organelle 
membranes with polyunsaturated fatty acids (PUFA), 
such as linoleic acid, being primary targets [76]. The 
downstream products of PUFA peroxidation, mostly 
4-hydroxynonenol (4-HNE), malondialdehyde 
(MDA), and acrolein, form irreversible protein 
adducts, leading to prolonged oxidative stress and 
consequent apoptosis [77]. While RaST is known to 
induce ROS, its mechanism of action has not been 
explored. We first quantified the ROS that RaST 
produces by measuring the levels of hydroxyl and 
peroxyl radicals in MM1.S cells with H2DCFDA 
fluorogenic dye 72 h after treatment. We found that 
RaST induced significantly higher amounts of ROS in 
cells treated with VLA-4-TC-NM RaST compared to 
untreated cells (P = 0.01) or the cells treated with 
either VLA-4-TC-NM (P = 0.01) or [18F]FDG (P = 0.03) 
(Figure 3A). The persistently elevated ROS levels 
correlated with an increase in hydroperoxidized 
lipids, which also increased to a lesser extent with 
VLA-4-TC-NM alone (Figure 3B). Analysis of data 
obtained from mass spectrometry identified 3β,5α,6β- 
trihydroxycholestane (triol), 7-ketocholesterol, and 
malondialdehyde downstream effectors of lipid 
hydroperoxidation (Figure 3C). Thus, we uncovered 
with experimental evidence that the hydro-
peroxidized lipids profile points to a mechanism 
where lipid hydroperoxidation is a critical upstream 
event leading to MMC apoptosis of RaST treated cells. 
The photophysical nature of the treatment via 
cytotoxic ROS generation complements current 
combination pharmacologic drugs that utilize other 
mechanisms of action. 
VLA-4-TC-NM RaST induces apoptosis and 
DNA double-strand breaks 
Enhancement of lipid-protein adducts directly 
activates caspase-3, leading to apoptosis [78]. 
Therefore, we investigated the state of caspase-3 
activation in VLA-4-TC-NM RaST-treated and 
untreated MM1.S cells. Although [18F]FDG and 
VLA-4-TC-NM increased caspase-3 levels up to two- 
and five-folds, respectively, RaST induced a ten-fold 
higher level of the enzyme than the untreated control 
72 h post-treatment (Figure 3D). The upregulation of 
caspase-3 is a reversible process that does not 
necessarily culminate in apoptosis-mediated cell 
death. Using the propidium iodide, we found a direct 
correlation between activated caspase-3 and cell 
death. VLA-4-TC-NM RaST mediated cell death was 
significantly higher than either of the controls, 
[18F]FDG (P = 0.01), and VLA-4-TC-NM (P = 0.04) 
(Figure 3E). 
Protein adducts resulting from 
hydroperoxidation of PUFA have been shown to 
interfere with the DNA repair function of p53 [77, 79]. 
Therefore, we investigated the downstream effects of 
p53 mediated DNA repair by measuring the levels of 
γ-H2A histone family member X (γ-H2AX), a 
precursor to DNA repair complex assembly and a 
direct indicator of the DNA double-strand breaks 
repair activity [71, 80]. Our result showed that 
VLA-4-TC-NM RaST significantly increased the 
γ-H2AX level compared to controls (Figure 3F). These 
changes occurred predominantly in the S phase of cell 
cycle (Figure 3F), suggesting that VLA-4-TC-NM 
RaST interferes with the cells' ability to synthesize 
DNA [81]. The ensemble of the functional data points 
to a mechanism where VLA-4-TC-NM RaST initiates 
lipid peroxidation that leads to apoptosis (Figure 4A) 
at levels that are significantly higher than those 
generated by either [18F]FDG or VLA-4-TC-NMs 
alone. 
VLA-4 RaST Upregulates intracellular 
pro-Apoptotic mediators of cell death 
Oxidative stress exerted on a cell induces a 
number of pro- and anti-apoptotic events, including 
the upregulation of p53, Bcl-2 antagonist/killer 
(BAK), Bcl-2-associated X protein (BAX) and Bcl-2 
proteins [82-84]. To investigate whether RaST 
modulates the expression of these proteins, we treated 
MM1.S cells by RaST, [18F]FDG or NMs alone for 72 h 
and analyzed the data relative to the untreated 
control. The individual proteins were then resolved 
with an SDS-PAGE and identified by Western blotting 
with appropriate antibodies. Our data showed that 
RaST upregulated the expression of BAX, Bcl-2, and 
p53, but not BAK (Figure 3G), suggesting that BAK 
protein, which is generally associated with the Bcl-2 
family of proteins [85], was not involved in RaST 
mediated cell death (Figure 4A). These results 
highlight a RaST-induced apoptosis mechanism in 
MM1.S cells via BAK-independent Bcl-2/BAX axis. 
Ferroptosis inhibitor abrogates RaST effect 
Ferroptosis is a distinct form of programmed cell 
death that emanates from iron-dependent lipid 
peroxidation [86, 87]. Fenton reactions involving Fe2+ 
ions from the intracellular labile iron pools and 





peroxides are major contributors to intracellular lipid 
peroxidation under physiological conditions. 
Previous studies provided compelling evidence 
regarding the biochemical similarities of Ti(IV) and 
Fe(III) [88]. During RaST, TC produces Ti-centered 
radicals that could induce ferroptosis. Therefore, we 
used Ferrostatin-1 (FST1), an inhibitor of ferroptosis 
[89, 90], to investigate the contribution of this cell 
death mechanism to RaST. Whereas RaST inhibited 
cancer proliferation by 50%, the addition of FST1 
restored cell viability, providing evidence for the role 
of ferroptosis in RaST-mediated cell death (P = 0.01; 
Figure 3H). 
RaST upregulates pro-apoptotic and 
downregulates pro-survival proteins 
RaST has the potential to perturb multiple 
pathways associated with cell death. To assess the 
dynamic changes, we performed label-free MS 
proteomics with lysates from MM1.S cells treated 
with VLA4-TC-NM RaST and the untreated controls. 
Using RaST cutoff ratios of ≥ 1.5 (upregulated) and ≤ 
 
 
Figure 3. Mechanism of VLA-4-TC-NM RaST. (A) VLA-4-TC-NM RaST generates significantly more ROS (P=0.0039) compared to either [18F]FDG (NS) or 
VLA-4-TC-NM alone (NS) when compared to no treatment; 4 x 105 MM1.S cells were treated with [18F]FDG, VLA-4-TC-NM, VLA-4-TC RaST, or left untreated. ROS 
measurements were performed 72 h later using H2DCFDA. (B) Hydroperoxydation of PUFA increased in cells treated with VLA-4-TC-NM RaST. MM1.S cells were plated and 
treated as in (A). The level of PUFA hydroperoxidation was measured with a lipid peroxidation assay 72 h later. VLA-4-TC-NM and VLA-4-TC-NM RaST produced significantly 
more lipid hydroperoxidation (P = 0.001 and P < 0.0001, respectively) than no treatment control. (C) VLA-4-TC-NM RaST-induced PUFA hydroperoxidation generated reactive 
aldehydes 72 h after administration. The cells were treated with VLA-4-TC-NM RaST or left untreated. 3ß,5α,6ß-THC-triol, 7-ketocholesterol, and malondialdehyde levels were 
significantly higher (P = 0.02, P = 0.02, P = 0.009, respectively) in treated cells; multiple t-tests were used for the statistical analysis. (D) Caspase-3 level was significantly higher 
in cells treated with VLA-4-TC-NM RaST compared to [18F]FDG and VLA-4-TC-NM (P < 0.0001 and P = 0.003, respectively) after 72 h of treatment; one-way ANOVA and 
Tukey's multiple comparisons tests were used for the statistical analysis. (E) Treatment of MM1.S cells with VLA-4-TC-NM RaST significantly increased the cell death 
(VLA-4-TC-NM RaST versus untreated: P = 0.0003; VLA-4-TC-NM RaST versus [18F]FDG: P = 0.005; VLA-4-TC-NM RaST versus VLA-4-TC-NM: NS). The cells were treated 
as in (A). After 72 h, the cells were treated with 0.1 µg PI, and the amount of cell-associated PI was determined with Flow Cytometry; one-way ANOVA and Tukey's multiple 
comparisons tests were used for the statistical analysis. (F) dsDNA breaks were significantly more abundant 72 h after VLA-4-TC-NM RaST. The cells were treated as in (A). 
After 72 h, the cells were stained with anti-γH2AX and DAPI. Flow Cytometry analysis showed an overall increase in dsDNA breaks during the S-phase. Specifically, dsDNA 
breaks were significantly more frequent during VLA-4-TC-NM RaST treatment compared to VLA-4-TC-NM (P = 0.003), [18F]FDG (P = 0.0002), and the untreated cells (P < 
0.0001); 2way ANOVA and Tukey's multiple comparisons tests were used for the statistical analysis. (G) Western blotting showed increased levels of apoptosis-related proteins 
72 h after VLA-4-TC-NM RaST. The cells were treated as in (A). (H) Ferroptosis inhibitor Ferrostatin-1 significantly inhibited VLA-4-TC RaST mediated cell death (P = 0.015). 
MM1.S cells were plated as in (C). Ferrostatin-1 was administered concomitantly with VLA-4-TC RaST and VLA-4 control at the final concentration of 10 µM. Three-way 
ANOVA and Tukey’s multiple comparisons tests were used for statistical analyses. 





0.5 (downregulated) for the treated to untreated cell 
lysate (RaST/NT), we identified 23 upregulated and 7 
downregulated proteins (Figure 4B, Supplementary 
Table 1). Among the upregulated proteins, we 
identified IRF2BPL gene product (RaST/NT = 2.22) 
and ribosomal protein S15 (RaST/NT = 4.08), which 
are involved in the cellular response to genotoxic 
stress through the p53 related mechanism. 
Apolipoprotein A1 (RaST/NT = 2.31) is a component 
of PUFA metabolism. In addition to p53 and PUFA 
pathways, serine hydrolase dipeptidyl peptidase 
(RaST/NT = 2.22) and nucleoporin POM121 
(RaST/NT = 1.96) are implicated in apoptotic 
pathways. The Ubiquitin-proteasome system 
components, Ubiquitin E2 (RaST/NT = 2.04) and 26S 
(RaST/NT = 1.6), are involved in regulating 
proteolysis. The upregulation of multicopper oxidase 
enzyme F5 (RaST/NT = 1.8), responsible for 
inhibiting lipid hydroperoxidation and Fenton 
reaction, illustrates how MM1.S cells mount 
countermeasures to inhibit the effects of cytotoxic 
ROS in response to RaST generates. Beside 
upregulating pro-apoptotic, RaST also downregulated 
multiple pro-survival molecules such as those 
involved in mRNA translation (ATXN2; RaST/NT = 
1.6), protein-protein interactions (PDLIM3; (RaST/NT 
= 0.4), and fatty acid biosynthesis (OXSM; (RaST/NT 
= 0.5). 
Overall, these results point to the lipid 
hydroperoxidation of PUFA by ROS as the event 
proximal to RaST agents’ internalization. The 
downstream events likely included the generation of 
α,ß-aldehydes and protein adducts culminating in cell 
death mediated by mitochondrial and caspase- 
dependent mechanisms [91-93]. The combined 
suppression of pro-tumor and upregulation of 
antitumor proteins, as well as ferroptosis, enable RaST 
to utilize multidimensional cell death mechanisms to 
destroy cancer cells and overcome ROS-resistance 
pathways cancer develop in response to treatment. 
Respective expression of VLA-4 and αvß3 in 
MM and OCs and GLUT1 in both cell types 
enable orthogonal RaST 
Interactions between MMC and OCs determine 
extensive osteolysis and promote MMC proliferation 
and resistance to antitumor immunity [94]. Inhibition 
of OC activity with bisphosphonates such as 
pamidronate and zoledronic acid relies on the high 
affinity of these drugs for hydroxyapatite in the bone 
matrix. Although combination therapies that include 
bisphosphonates have improved skeletal health for 
 
 
Figure 4. RaST induces multiple cell death pathways. (A) Proposed mechanisms of RaST-induced multidimensional cell death pathways. Red arrows are based on data 
presented in this manuscript. (B) Ratios of relative abundances of proteins from either VLA4-TC-NM RaST treated cells or the untreated cells (RaST/NT). Red filled circles: 
RaST/NT ≥ 1.5; green filled circles: RaST/NT ≤ 0.5. Triplicates of each experimental condition were analyzed. 





MM patients, toxicity of bisphosphonates, incomplete 
blockade, or reduced availability of bone matrix to 
bind bisphosphonates (due to osteoblast inhibition) 
combine to mitigate their routine use in the clinic. The 
newer and improved denosumab therapy [32] has 
shown impressive results, with the drawback that 
precursors can still differentiate once the antibody is 
cleared. Instead of indiscriminately targeting skeletal 
bone matrix or inhibiting the function of OCs with 
different drugs, we explored a treatment paradigm 
that uses the same drug (TC) and 
radiopharmaceutical ([18F]FDG) RaST to deplete both 
tumor-associated OCs and disrupt the MM-OC 
interaction during therapy. This strategy requires 
orthogonal delivery of TC to OC and MM cells. Unlike 
metastatic breast cancer to the bone where αvß3 is 
expressed in both cancer cells and OCs, we found that 
MM1.S cells were positive for VLA-4 (CD49d), but not 
αvß3 (CD61) (Figure 5A). Treatment of MM1.S with 
VLA-4-TC-NM or combined treatment with VLA-4- 
TC-NM and αvß3-TC-NM, followed by [18F]FDG 
showed that the combination RaST was as effective as 
the VLA-4 RaST alone (Figure 5B), demonstrating that 
the low αvß3 expression prevents the contribution of 
TC-loaded αvß3-targeted NM to RaST effect on 
MM1.S cells in vitro. 
Cells exist in 3D in vivo via cell-cell interactions 
that require adhesion molecules. As exposure to the 
BME can alter integrin expression [46], we determined 
if the target integrin expression on cancer cells and 
OCs were retained. After establishing MM1.S in mice, 
we isolated the bone marrow to measure CD61 
expression by flow cytometry. Anti-human CD61 
antibody, while efficiently staining the highly 
ß3-expressing MDA-MB-231 breast cancer cells, was 
negative for MM1.S, demonstrating that MM1.S 
express low to no αvß3 in BME in vivo (Figure 5C). 
This finding suggests that αvß3 targeting would be 
largely ineffective on MM1.S in vivo. Expectedly, we 
found that OCs isolated from murine bone marrow 
expressed a significantly higher level of αvß3 in vitro 
(Figure 5D), supporting the potential use of αvß3 to 
target OC for orthogonal strategy. Selective delivery 
of [18F]FDG to target cells requires the expression of 
GLUT1 on both MM1.S and OCs and cancer cells. 
Western blot shows that myeloma cell lines MM.1S 
and 5TGM1 and, to a lesser extent, murine OCs 
express GLUT1 (Figure 5D). Extension of in vitro RaST 
to TC-loaded αvß3 NM in OCs showed a response 
similar to the VLA-4-TC-NM RaST in MM1.S cells 
(Figure 5E), indicating that under similar conditions, 
both VLA-4 and αvß3 targeted NMs are capable of 
delivering a sufficient amount of TC into their 
respective target cells and the GLUT1 level is capable 
of initiating RaST in both cell types. The differential 
expression of the target biomarkers allowed us to 
experimentally dissect the effects of combination 
RaST on tumor and OC cell populations in vivo. 
 
 
Figure 5. (A) CD49d and CD61 expression by MM1.S cells in culture; MM1.S cells were grown in culture with CM for 1-3 weeks prior to flow cytometry analysis. (B) 
VLA-4-TC-NM RaST and VLA-4-TC-NM + αvß3-TC-NM RaST comparison in MM.S1 cells in vitro. (C) αvß3 expression by MM1.S cells in vivo compared to a control. Animals with 
disseminated MM were euthanized 2-4 weeks after the inoculation and the bone marrow (BM) was examined with flow cytometry for αvß3 expression. MDA-MB-231 human 
mammary adenocarcinoma cells grown in culture were used as a positive control. (D) αvß3 and GLUT1 expression by murine OCs. Bone marrow from femurs and tibias of 5 
weeks old C57BL/6-KaLwRij male mice was harvested and differentiated to OCs as described in Shioi, et al. [68]. Proteins of interest detected with GLUT1 (clone D3J3A Rabbit 
mAb) and αvß3 (clone SJ19-09) antibodies. (E), αvß3-TC-NM RaST in OC in vitro. OCs were differentiated from BMM for 7-14 days prior to the experiment. αvß3-TC-NM RaST 
was performed as in (B). Averages of each dataset were compared to the untreated control using a one-way ANOVA and Tukey's multiple comparisons test. 






Figure 6. Dual cancer-osteoclast RaST in mice. (A) Fox Chase SCID beige MM1.S xenograft animals untreated or treated once weekly for five weeks with αvß3-TC-NM 
RaST, VLA-4-TC-NM RaST, and αvβ3-TC-NM + VLA-4-TC-NM RaST; MM1.S/CBR/GFP cells (1 x 106 cells per animal) were implanted IV and the therapy was initiated after the 
whole body radiance reached 1 x 106 photons/sec/cm2/steradian (p/s/cm2/sr). Tumor progression was monitored with weekly BLI. αvβ3-TC-NM + VLA-4-TC-NM RaST 
significantly reduced tumor progression compared to no treatment (P = 0.0007). (B) Representative bioluminescence images of Fox Chase SCID beige MM1.S xenograft animals 
treated with αvβ3-TC-NM + VLA-4-TC-NM RaST and the untreated controls. (C) C57BL/6-KaLwRij 5TGM isograft animals were implanted with 5TGM/CBR/GFP cells (1 x 106 
cells per animal) and monitored as in (A). The test animals were untreated or treated once weekly for five weeks with αvβ3-TC-NM RaST, VLA-4-TC-NM RaST, and 
αvβ3-TC-NM + VLA-4-TC-NM RaST. αvβ3-TC-NM + VLA-4-TC-NM RaST significantly inhibited tumor progression compared to no treatment (P = 0.0317). (D) 
Representative bioluminescence images of C57BL/6-KaLwRij 5TGM isograft animals treated with αvβ3-TC-NM + VLA-4-TC-NM RaST and the untreated controls. Two-way 
ANOVA and Tukey's multiple comparisons were used for the statistical analysis. 
 
In vivo depletion of OCs potentiates MM 
response to RaST via orthogonal cellular 
VLA-4 and αvß3 targeting strategy 
To demonstrate the application of the combined 
therapy in vivo, we used two animal models of MM. A 
previous study showed that RaST was able to inhibit 
MM1.S proliferation and improved survival in an 
immunocompromised model, although the tumors 
relapsed due to minimal residual disease that did not 
respond to treatment [43]. In this study, we assessed 
whether the inactivation of OCs would enhance RaST 
effect. MM1.S/CBR/GFP cells were injected 
intravenously into Fox Chase SCID beige mouse 
strain. The animals were monitored with BLI to detect 
the appearance of skeletal tumor lesions. We initiated 
treatments when the total photon flux from the 
tumors reached 1 × 106 and continued once weekly for 
five weeks. The animals were imaged once a week 
and the total photon flux representing the viable 
MM1.S cells was recorded. Data analysis showed that 
VLA-4-TC-NM RaST alone produced initial tumor 
inhibition, which was followed by an increase in 
tumor growth (Figure 6A, B) similar to what was 
reported previously [43]. Surprisingly, αvß3-TC-NM 
RaST also suppressed tumor growth compared to the 
untreated control, with P = 0.006. Given that MM1.S 
cells do not express αvß3, our result provides new 
evidence that depletion of OC could disrupt MM-OC 
interactions or communication networks involved in 
promoting MMC survival [17, 19, 52]. The unique 
advantage of the orthogonal multicellular over 
monocellular therapies was evident with the 
combination αvß3-TC-NM + VLA-4-TC-NM RaST, 
resulting in unprecedented progression-free survival 
(P = 0.0007) for this MM model. 
Next, we evaluated if the bimodal RaST will 
improve MM treatment response in an 
immunocompetent syngeneic murine model for MM 
by inoculating 5TGM1/CBR/GFP (1 x 106 per mouse) 
cells in C57BL/6-KaLwRij mice [95]. All animals were 
monitored with BLI and treated as described above. 
Whereas mice treated with αvß3-TC-NM RaST or 
VLA-4-TC-NM RaST alone did not exhibit statistically 
significant tumor response compared to the untreated 
animals, the combination αvß3-TC-NM + 
VLA-4-TC-NM RaST significantly inhibited tumor 
growth (Figure 6C, D). Surprisingly, enhanced tumor 





proliferation was observed in the VLA-4-TC-NM 
RaST only mice after day 28 (Figure 6C). As 
previously reported, immune (T and NK) cells, which 
are absent in Fox Chase SCID beige, have high VLA-4 
expression [96, 97]. A likely scenario is that VLA-4 
NM distributed TC to MM and immune cells, 
depending on the relative expression levels of the 
targeted biomarker. Under this condition, the net 
amount of TC available to RaST is below the threshold 
required to exert a therapeutic effect. Consistent with 
this observation, the correlative increase, albeit 
gradual, of tumor growth in the combination therapy 
group could be attributed to the diminishing effect of 
VLA-4 delivered TC in MMC. Similarly, immune cells 
also express αvß3 [98], which can account for the 
moderate initial response in the αvß3-TC-NM RaST 
treated mice before following the trajectory of the 
untreated mice. Regardless of the relatively poor 
response using the single RaST approach, the 
sustainable αvß3-TC-NM + VLA-4-TC-NM RaST 
response suggests that targeting cancer and multiple 
cells in BME could have a synergistic effect in cancer 
therapy. 
These data point to a strategy wherein sufficient 
doses of TC could be delivered locally in the bone to 
MM, OC, and select immune cells for RaST-mediated 
simultaneous depletion to achieve complete treatment 
response. The impressive result from combination 
RaST in immunocompetent mice suggests that using 
targetable biomarkers that activate antitumor immune 
cells could improve progression-free survival in 
immunocompetent mouse models. As novel 
combination drug therapies are in high demand for 
MM, RaST elicits diverse cell death pathways that will 
complete the standard of care MM therapies. 
An important assumption in this study is that 
αvß3-TC-NM RaST will deplete OCs in vivo. 
Therefore, we investigated the status of these cells in 
RaST-treated mice with tartrate-resistant acid 
phosphatase (TRAP), which is widely used as an 
accurate marker of OC function and population in vivo 
[58, 99, 100]. The relative abundance of OC was 
assessed by quantifying TRAP-positive cells in the 
bones of untreated and RaST treated (αvß3, VLA-4, or 
αvß3 + VLA-4 TC loaded NMs) mice using either the 
MM1.S or 5TGM models as described above. RaST 
was administered three times, followed by harvesting 
of femurs for TRAP immunohistochemistry. 
TRAP-stained OCs were visible on the bone surface of 
untreated mice (Figure 7A,B). Analysis of 
TRAP-positive cells revealed that αvß3-TC-NM and 
αvß3-TC-NM + VLA-4-TC-NM RaSTs were equally 
effective in eliminating OC in vivo in the MM1.S 
xenograft (Figure 7A) and 5TGM isograft (Figure 7B) 
models, as revealed by the reduced or discontinuous 
TRAP-stain. Quantification of the data showed that 
5TGM MM exhibited about a 3-fold decrease in OC 
relative to controls (Figure 7D), but a marginal 
reduction in the OC population was observed for 
VLA-4-TC-NM RaST. A similar trend was found in 
the immunocompromised mouse model, with about a 
two-fold decrease of OCs in αvß3-TC-NM RaST from 
control (Figure 7C). Expectedly, the combination 
αvß3-TC-NM + VLA-4-TC-NM RaST exhibited a 
similar profile as αvß3-TC-NM RaST alone. These 
observations confirm that αvß3-TC-NM RaST is 
primarily responsible for inhibiting osteoclastogenesis 
and combines with VLA-4-TC-NM RaST to potentiate 
MM treatment response. 
Discussion 
Traditional combination chemotherapies 
typically use two or more pharmacologic agents to 
sustain therapeutic effects in cancer cells [101], but 
these drugs also introduce cumulative side effects. 
Particularly, MM is a fatal malignancy that requires a 
multidrug therapeutic regimen to overcome 
non-responsiveness and resistance. However, 
end-organ damage, age, and co-morbidities render 
MM patients fragile, further preventing aggressive 
treatments due to off-target toxicities. To minimize 
systemic and organ toxicities, we pioneered a unique 
treatment paradigm, RaST, which is based on the 
orthogonal delivery of individually nontoxic amounts 
of a light-sensitive drug and a radiopharmaceutical to 
cancer cells where they converge to produce toxic 
amounts of ROS [42, 43]. RaST has the unique 
advantage of using a photophysical ROS-generating 
mechanism to eradicate target cells, regardless of their 
origin. This scenario allowed us to use a single 
photosensitizer (TC) instead of multiple drugs for 
simultaneous MM-stromal cell therapy. Our data 
highlights multiple cell death pathways involved in 
TC-mediated RaST. First, RaST stimulates lipid 
hydroperoxidation of PUFA [77, 102-105], a process 
that produces various α,ß-aldehydes known to form 
irreversible function-perturbing protein adducts and 
culminates in caspase-3 independent apoptosis 
induction (Figure 4A). Second, RaST also utilizes a 
caspase-3 dependent apoptosis pathway via 
Bax-independent Bak/Bcl-2 axis. Both of these 
apoptosis-mediated cell death pathways emanate 
from ROS generation. Third, VLA-4-TC NMs induce 
double-stranded DNA breaks by a ROS-independent 
pathway [106] that relies on stable titanium-centered 
radicals to produce DNA damage [42]. While this 
mechanism may have limited contribution to cell 
death due to the small doses used, it reveals another 
path that could create a multidimensional 
combination therapy that uses TC as both a 





photosensitizer and a pharmacologic drug at higher 
doses. Finally, the surprising observation of 
ferroptosis as a contributor to RaST-mediated cell 
death points to a mechanism in which the biochemical 
similarity of iron and titanium ions [88] enhance the 
Fenton reaction during TC-mediated RaST. Based on 
the above processes, the observed delay in the 
effective killing of MM cells following RaST was not 
surprising as these cell death pathways are not 
instantaneous. During this progressive cell death 
process, it is possible to amplify the treatment 
response by adding specific pharmacological drugs 
that leverage any of the above pathways to minimize 
residual disease. 
Our study reveals the effectiveness of 
orthogonally targeting RaST against cancer cells and 
their microenvironment in both immunocompetent 
and immunocompromised MM mouse models. While 
VLA-4 RaST primarily accounted for anti-myeloma 
activity in vitro, both αvß3 and VLA-4 RaST 
individually exerted a therapeutic effect on MM in 
both models. The data illustrates how disruption of 
cancer-bone cell communication network alone using 
the non-MM targeting αvß3-TC-NM could inhibit 
cancer proliferation. Other studies have shown that 
treatment of MM with the anti-resorptive bone agent, 
zoledronic acid [107], and the Receptor Activator of 
NF-kB ligand (RANKL) inhibitor, denosumab [32] 
reduced osteolysis and inhibited MM progression 
[108]. Unfortunately, renal clearance of 
bisphosphonates has often raised concerns for their 
tolerability in MM [32], and rebound effects due to 
activation of stalled OC precursors upon 
discontinuation of denosumab are an emerging 
weakness of antibody treatment [109]. Although our 
single cell-targeted RaST does not have similar 
 
Figure 7. αvß3-TC-NM RaST leads to OC depletion. (A) OCs in femurs of Fox Chase SCID beige MM1.S xenograft and B, C57BL/6-KaLwRij 5TGM isograft treated with 
indicated RaST and visualized with TRAP immunohistochemical stain. OC content in (C), Fox Chase SCID beige MM1.S xenograft and (D), C57BL/6-KaLwRij 5TGM isograft was 
quantified as the total number of TRAP-positive cells per section using Zeiss ZEN 2.3 software. In both models, αvß3-TC-NM RaST, either alone or in combination with 
VLA-4-TC-NM, significantly reduced the OC population (Fox Chase SCID beige MM1.S xenograft: P = 0.0005 and P = 0.0006, respectively; C57BL/6-KaLwRij 5TGM isograft: P 
< 0.0001 and P < 0.0001, respectively). Two-way ANOVA and Tukey's multiple comparisons were used for statistical analysis. 
 





limitations, all treated animals experienced MM 
rebound after a latent period, similar to what is found 
in standard therapies. Implementation of the MM-OC 
combination RaST using αvß3-TC-NM + VLA-4-TC- 
NM in vivo achieved prolonged progression-free 
survival for these mice. These data provide evidence 
that the dual targeting of cancer cells and their 
microenvironment can reduce both osteolysis and 
MM tumor burden in vivo by depleting OCs within 
the tumor region. 
We found stark differences in treatment 
response between the immunocompetent and 
immunocompromised MM models. Not only did 
VLA-4 RaST have a negligible effect on tumor 
progression compared to the untreated control, but 
the tumor cells in treated mice also appeared to 
proliferate at a faster rate than control in the 
immunocompetent model. At the low dose of TC used 
in this study, the presence of VLA-4 expressing 
immune cells in this model could reduce the effective 
dose of TC available for effective RaST in MM cells, 
which was not the case in the immunocompromised 
model. Similarly, the αvß3 RaST followed a similar 
trajectory as the untreated control, albeit with low 
tumor inhibition at the early stages. Histological 
assessment of bone tissue in both mouse models 
reveals that at basal levels, the OC population was 
higher in C57BL/6-KaLwRij strain relative to the Fox 
Chase SCID beige strain. Logically, this imposes a 
higher threshold of OC depletion in the 
immunocompetent model to achieve a therapeutic 
effect, which accounts in part for the limited 
inhibition effect on MM. The fact that the combination 
of two apparently ineffective VLA-4 and αvß3 RaST 
inhibited tumor growth in vivo supports a treatment 
paradigm where the perturbation of communication 
between cancer and multiple enabling cells can 
synergize to exert durable tumor inhibition. 
Collectively, this study elucidates the 
multidimensional cell death mechanism that RaST 
uses to exert a therapeutic effect. It also uncovers an 
orthogonal multicellular treatment paradigm 
targeting both cancer cells and their 
microenvironment by activating the same drug type 
to enhance cancer therapy. By using a photophysical 
method to produce cytotoxic radicals in target cells, 
the dual cell targeting RaST strategy can add a new 
dimension to current combination therapies that only 
use pharmacologic drugs. In particular, the latent 
period between therapy initiation and the onset of cell 
death (3 days) provides a therapeutic window when 
cancer cells are most vulnerable to additional assaults. 
This timing could be utilized to eradicate residual 
disease before it transforms into a therapy-resistant 
phenotype. 
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